http://www.youtube.com/watch?v=vwRIdWf-sE4

Cabergoline 2012 – Health Medicine
Cabergoline 2012 – Health Medicine. When Cabergoline, which is the derivative of ergot, is on the D2 receptors it is a potent dopamine receptor agonist. It's brand names are Cabaser and Dostinex. The study of rats in Vitro shows that the inhibitory effect on the cells known as pituitary lactotroph (prolaction) was direct. Its affinity for the receptor sites of D2 is high and that is why it is mainly used as a first line agent to manage prolactinomas. In 1981/82 the scientists who were working in Milan invented Cabergoline; these scientists were working in a drug company, which was owned by Italy, called Farmitalia-Carlo Erba Spa. They were experimenting with derivatives of ergot alkaloids which were semisynthetic. In 1992 Pharmicia acquired Farmitalia-Carlo and in 2002 Pfizer in turn acquired this company. The FDA approved the drug on December 23, 1996 and when the US patent expired in the late 2005, this drug became generic. A patent application for the Cabergoline was filed by Farmitalia in 1982, and in July 1985 the US Patent 4526892 was issued. Cabergoline has a significant affinity for the receptors of alpha;2B-, 5-HT2C, 5-HT2B, 5-HT2A, 5-HT1A, D4 and D3 even though it is described mainly as the agonist of the dopamine D2 receptor. It has low to moderate affinity for the receptors of the 5-HT7 and D1. In all the receptors, Cabergoline is an agonist however it is an antagonist in alpha;2B- and 5-HT7. The resorption of the Cabergoline from the tract known as gastrointestinal (GI …

By: resumesanta<span style="color: #666666; font-size: 11px;"

Excerpt from:
Cabergoline 2012 – Health Medicine – Video

Source:
http://www.longevitymedicine.tv/cabergoline-2012-health-medicine-video/